Regeneron Announces Upcoming Investor Conference Call

Saturday, March 9, 2019 Press Release
Email Print This Page Comment bookmark
Font : A-A+

TARRYTOWN, N.Y., March 8, 2019 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management

participation as follows:

  • J.P. Morgan 2019 Spring Biotech Conference Call Series at 1:00 p.m. Eastern Time on Friday, March 15, 2019

The session may be accessed from the "Investors

& Media" page of Regeneron's website at http://investor.regeneron.com/events.cfm.  A replay of the webcast will be archived on the Company's website and will be available for 30 days.

About Regeneron Pharmaceuticals, Inc. Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neuromuscular diseases, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite® technologies, such as VelocImmune® which produces optimized fully-human antibodies, and ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world.

For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.

Contact Information: Investor Relations Mark Hudson 914.847.3482 mark.hudson@regeneron.com 

Corporate Communications Alexandra Bowie 914.847.3407 alexandra.bowie@regeneron.com 

 

Cision View original content:http://www.prnewswire.com/news-releases/regeneron-announces-upcoming-investor-conference-call-300809394.html

SOURCE Regeneron Pharmaceuticals, Inc.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store